Abstract: This study investigates the effects of statin on left ventricular ejection fraction and mortality and morbidity in patients with heart failure for one year. The function of LV is detecting the survival of patients with CHF. So we use statin in those with previously stable CHF. A total of 200 patients with L.VEF = 40% were randomized for one year with statin (20 mg) (n= 100) or placebo (n = 100) in addition to routine treatment for CHF. The end point of this study is the effect of statin on LV EF and mortality and morbidity of patients with CHF. The LV EF was similar in both groups at base line (statin :35 ±6% PLB: 35±7% ) and after one year of treatment ( mean difference 1.49% p = 0.1) there were significantly more adjudicated morbidity in the placebo group (n = 28[25%]), statin (n = 10[8%] p = 0.005) but no significant difference between group for mortality. A proportion of patients withdrew from each treatment group because of (incomplete follow). After one year treatment. Statin group improved symptoms and morbidity than PLB groups, but didn’t change mortality and LVEF. A randomized placebo controlled trial assessing the effects of statin on echocardiography function and mortality and morbidity in patients with LVEF = 40%. We compared the effect of statin with placebo on cardiac function in patients with congestive heart failure. Statin treatment affect left ventricular ejection fraction compared with placebo ( mean difference-0.65% , p<0.0001) and significant improvements in morbidity but no affect on mortality (mean difference 1.50% p = 0.1).